WO2004064830A1 - Compositions de matiere grasse traitees pour prevenir et traiter des maladies associees au mode de vie - Google Patents

Compositions de matiere grasse traitees pour prevenir et traiter des maladies associees au mode de vie Download PDF

Info

Publication number
WO2004064830A1
WO2004064830A1 PCT/JP2004/000599 JP2004000599W WO2004064830A1 WO 2004064830 A1 WO2004064830 A1 WO 2004064830A1 JP 2004000599 W JP2004000599 W JP 2004000599W WO 2004064830 A1 WO2004064830 A1 WO 2004064830A1
Authority
WO
WIPO (PCT)
Prior art keywords
fat
oil
group
dehydrogliasperin
glycillin
Prior art date
Application number
PCT/JP2004/000599
Other languages
English (en)
Japanese (ja)
Inventor
Tatsumasa Mae
Toshinori Ikehara
Naoki Arai
Hideyuki Kishida
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to JP2005508126A priority Critical patent/JPWO2004064830A1/ja
Publication of WO2004064830A1 publication Critical patent/WO2004064830A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Oil processing composition for prevention and improvement of lifestyle-related diseases Oil processing composition for prevention and improvement of lifestyle-related diseases
  • the present invention is for preventing and / or improving lifestyle-related diseases which can be used in foods and drinks such as health foods and functional health foods (food for specified health use, nutritional foods), pharmaceuticals, quasi-drugs, cosmetics, etc.
  • the present invention relates to an oil and fat composition of Background art
  • lifestyle-related diseases caused by deterioration of lifestyle such as overnutrition and lack of exercise have become a major social problem.
  • the lifestyle-related diseases here include visceral fat obesity, type 2 diabetes, hyperlipidemia, hypertension, and the like, and the multiple-risk 'factor syndrome, which eventually worsens to arteriosclerosis. Therefore, a composition having the effect of preventing and / or improving these lifestyle-related diseases is desired, and the form of the composition is a health food or a health functional food (a food for specified health use, Foods and drinks such as nutritional foods), pharmaceuticals, quasi-drugs, and cosmetics are desired.
  • Multiple 'risk' factor syndromes are syndrome X due to Reaven X (Diabetes, 37, 1595-1607, 1988), quartet of death due to Kaplan (Archi Vesof Internal Medicine, 149, 1514-1520) Insulin Resistance Syndrome (Diabetes Care, 14, 173-194, 1991) due to DeFronzo, Visceral Fat Syndrome due to Matsuzawa (Diabetes / Metabo 1 ism Revi ewew) s, 13, 3–13, 1997), and the common causative factor of these syndromes is thought to be insulin resistance.
  • thiazolidine derivatives such as troglitazone, pioglitazone, and rosiglitazone, which are ligands for peroxisome proliferator-activated receptor ⁇ (peroxisome prollferator-activatedreceptory PP AR 7), have shown that these drugs are used in patients with type 2 diabetes. It has been shown to improve insulin resistance and show a hypoglycemic effect, and has been clinically applied as an insulin resistance ameliorating drug and a type 2 diabetes drug. Furthermore, it has been clarified that these thiazolidine derivatives increase subcutaneous fat but reduce visceral fat, and have a blood free fatty acid lowering action, a blood pressure lowering action, and a pile inflammatory action.
  • a compound having PPARy ligand activity improves insulin resistance and is effective in preventing and / or improving lifestyle-related diseases such as visceral fat obesity, type 2 diabetes, hyperlipidemia, and hypertension.
  • Licorice is a plant belonging to the genus Glycyrrhiza in the legume family, and is used for edible and medicinal purposes (herbal medicine).
  • the main varieties are Darikiruliza'Glabra (Glycyrrhizaglabra) and G. ensis) and G. infata (G. inf 1 ata).
  • All varieties contain glycyrrhizin (daricyrrhizic acid), a hydrophilic component, but the flavonoid, a hydrophobic component, contains specific compounds depending on the cultivar. This cultivar-specific flavonoid may be used to identify licorice varieties.
  • hydrophobic extracts containing a large amount of licorice flaponoids and having a very small amount of glycyrrhizin are multiple.Risk 'Factor' may be useful for prevention and / or improvement of symptomatic groups.
  • hydrophobic extract of licorice has P PAR ⁇ ligand activity, and its active ingredient is flavonoid, especially prenylflavonoid (WO 03-037316). Above all, the extract derived from G.
  • peralensis has high PPARV ligand activity, and the prenyl flavonoids contained in the extract, glycicumarin, glycillin, dehydrodariasperin C and dehydrodariasperin D, have high activity.
  • dehydroglasperin D is a compound newly found in WO 03/037316.
  • licorice hydrophobic flavonoids are hardly soluble in water, are easily solidified as they are extracted from organic solvents, and color change is rapid. Due to its nature, it is difficult to use. To solve this, licorice hydrophobic flavonoids are dissolved in medium-chain fatty acid triglycerides, and the licorice hydrophobic flaponoid preparations are used as antioxidants, antibacterial agents, enzyme inhibitors, coloring agents, antitumor agents, antiallergic agents, It is used as an antiviral agent, etc. (Patent No. 279443). However, in Patent No. 2794443, there is no limitation on the compound, and no use of the compound as a preventive and / or ameliorating agent for lifestyle-related diseases is known. Summary of the Invention
  • the present invention comprises at least one compound selected from the group consisting of glycicoumarin, glycillin, dehydroglasperin C and dehydrodariasperin D, and comprises a health food or a health functional food (specified health food, nutritional food). It is an object of the present invention to provide a composition for preventing and / or improving lifestyle-related diseases, which can be used for foods and drinks, pharmaceuticals, quasi-drugs, cosmetics, and the like.
  • the present inventors have conducted intensive studies in view of the above-mentioned circumstances, and as a result, it was possible to specifically dissolve glycicoumarin, glycillin, dehydrogliasperin C and dehydrogliasperin D in certain kinds of oils and fats. It has been found that the stability of these compounds is improved by dissolving them in fats and oils, and that the processability of foods and drinks, pharmaceuticals, quasi-drugs, cosmetics, and the like is also improved, and the present invention has been completed.
  • the present invention provides a lifestyle-related disease characterized by containing an oil or fat in which at least one compound selected from the group consisting of glycicoumarin, glycillin, dehydrogliasperin C and dehydrodaria sperin D is dissolved.
  • the present invention relates to a fat and oil processing composition for prevention and / or improvement, and a fat and oil processing composition for improving insulin resistance.
  • the present invention relates to glycicoumarin, glycillin, dehydrodaria sperin C and ⁇ using a composition containing an oil or fat in which at least one compound selected from the group consisting of dehydrodaria sperin D is dissolved, a method for preventing and / or improving lifestyle-related diseases, a method for improving insulin resistance,
  • the present invention relates to a method for preventing and / or improving hyperglycemia, and a method for reducing intraperitoneal fat.
  • the oil- and fat-processed la composition for preventing and / or improving lifestyle-related diseases is at least one compound selected from the group consisting of glycitamarin, glycillin, dehydrogliasperin C and dehydrogliasperin D. It is characterized in that it contains oils and fats in which is dissolved.
  • the oil / fat processing composition for improving insulin resistance ⁇ t of the present invention has at least one compound selected from the group consisting of glycicoumarin, glycillin, dehydrodariasperin C and dehydrogliasperin D dissolved therein. It is characterized by containing fats and oils.
  • the oil and fat processing composition of the present invention preferably contains, among the compounds, dehydrogliasperin D and at least one compound selected from the group consisting of glycicoumarin, glycillin and dehydrogliasperin C. Furthermore, it is more preferable that it contains dehydrologliasperin C and dehydrodariasperin D, and that it contains either glycicoumarin or glycillin. In particular, it is most preferable to include all of glycitamarin, glycillin, dehydrogliasperin C and dehydrogliasperin D.
  • the compound has PPARy ligand activity similarly to thiazolidine derivatives such as troglitazone pioglitazone, insulin resistance is improved, and visceral fat obesity, type 2 diabetes, hyperlipidemia, It is effective in preventing and / or improving lifestyle-related diseases such as blood pressure.
  • Glycicoumarin (g 1 ycycoumarin) and dalicillin (g 1 ycyrin) used in the present invention are flavonoids classified into 3-arycoumarin (3-arylcoumarin), and are represented by the following general formula (1).
  • dehydrodroglyasperin C and the dehydroglyasperin D used in the present invention are classified into isoflav-1-3-ene. It is a flavonoid and a compound represented by the following general formula (2).
  • Glicitamarin, glycillin, dehydrogliasperin C and dehydroglia sperin D are components that are specifically contained in Glycyrrhiza peralensis (G1ycyrrhiizarualensils) among licorice, and are hardly contained in other varieties. However, it may be included in hybrids between G. peralensis and other varieties.
  • the compound is separated from other flavonoid components by high-performance liquid chromatography (HPLC) using a reversed-phase column such as ODS (a packing material in which octadecylsilyl groups are chemically bonded to a silica gel carrier), and detected and quantified. can do.
  • the method for obtaining glycicoumarin, glycillin, dehydrogliasperin C and dehydrogliasperin D is not particularly limited. It can be obtained from cis licorice.
  • the method is not particularly limited, and examples thereof include extraction with an organic solvent such as ethanol, ethyl acetate, and acetone.
  • the compound is contained in the licorice hydrophobic extract obtained by the above extraction, and the compound may be used as it is, but it may be further purified or purified by column treatment, deodorization treatment, decolorization treatment, etc. Is also good.
  • any of compounds derived from other natural sources such as plants, chemically synthesized compounds, and those biosynthesized by cultured cells or the like can be used in the present invention.
  • the compound may be used in a purified form, but may be used in a crude form as long as it does not contain unsuitable impurities in foods and drinks, pharmaceuticals, quasi-drugs, cosmetics and the like.
  • the fats and oils used in the present invention include glycerin fatty acid esters.
  • the glycerin fatty acid ester is preferably a glycerin fatty acid ester containing a medium-chain fatty acid triglyceride and / or a glycerin fatty acid ester containing a partial glyceride.
  • the medium-chain fatty acid triglyceride or the partial glyceride preferably accounts for 50% by weight or more of the entire glycerin fatty acid ester, and particularly preferably accounts for 70% by weight or more.
  • Glycerin fatty acid esters containing 50% by weight of medium chain fatty acid triglyceride and 50% by weight of partial glyceride can also be used.
  • the medium-chain fatty acid triglyceride is a fatty acid having 6 to 12 carbon atoms as a constituent fatty acid.
  • the composition ratio of the fatty acid is not particularly limited, but the composition ratio of the fatty acid having 8 to 10 carbon atoms is 50 weight. /. More preferably, 70 weight. /. The above is more preferable.
  • medium chain triglycerides having a specific gravity of 0.94 to 0.96 at 20 ° C and a viscosity of 23 to 28 cP at 20 ° C are more preferable.
  • any of medium-chain fatty acid triglycerides, such as those of natural origin and those prepared by transesterification, can be used.
  • the partial glyceride is diglyceride (1,2-diacylglycerol, 1,3-diacylglycerol) or monoglyceride (1-monoacylglycerol, 2-monoacylglycerol). ). Any of the partial glycerides may be used, or a mixture of both may be used, but diglycerides are preferred from the viewpoint of processability.
  • partial glycerides are derived from natural sources and esters. Any of them, such as those prepared by exchange, can be used.
  • the partial glyceride those in which the constituent fatty acids have 6 to 24 carbon atoms are preferable.
  • a partial glyceride of a medium-chain fatty acid can be used.
  • the method for dissolving glycicoumarin, glycillin, dehydrogliasperin C and dehydrogliasperin D in fats and oils is not particularly limited, and can be carried out by ordinary operations such as stirring and mixing.
  • an extract containing the compound or a crude product of the compound since impurities other than the compound are contained, the compound is dissolved in fats and oils by stirring, mixing, etc., and then filtered, It is desirable to remove impurities insoluble in fats and oils by operations such as centrifugation.
  • a purified product of the compound is used, a homogeneous solution can be easily obtained.
  • a method of dissolving in an organic solvent such as ethanol in advance, mixing the solution with fats and oils, and then distilling off the organic solvent should be used. You can also.
  • glycicoumarin, quericillin, dehydrodaliasperia C and dehydrogloriasperin D are unstable at a temperature of 40 ° C or more in a powder state, and 25 in a solution in an organic solvent such as ethanol.
  • the compound is unstable at a temperature of not less than ° C, but is stable at a temperature of not less than 25 ° C when the compound is dissolved in the fat or oil used in the present invention.
  • the oil / fat processing composition for preventing and / or improving lifestyle-related diseases of the present invention is at least selected from the group consisting of visceral fat obesity, type 2 diabetes, hyperlipidemia and hypertension among lifestyle-related diseases. It can be preferably used for one disease, and more preferably for visceral fat type obesity and no or type 2 diabetes. More specifically, it can be preferably used for prevention and / or improvement of hyperglycemia and reduction of intraperitoneal fat.
  • the form of the processed fats and oils for preventing and / or improving lifestyle-related diseases and the processed fats and oils for improving insulin resistance of the present invention are not particularly limited in form. It can be used for foods and drinks such as foods and nutritional functional foods), pharmaceuticals, quasi-drugs, and cosmetics.
  • the fat or oil in which at least one of the dissolved compounds is dissolved can be used as it is alone for cooking, soft capsule preparation, lotion, and the like. Also, since it can be freely mixed with an oily object, it is possible to adjust the physical properties by mixing with other fats and oils according to the purpose.
  • the other fats and oils are preferably edible or medicinal, and the type and amount used are determined in consideration of the individual physical properties required for the product and various conditions such as the temperature range of use, and the type and use By adjusting the amount, characteristics such as consistency and melting point can be controlled.
  • oils and fats include, for example, vegetable oils such as corn oil, rapeseed oil, high cinnamon rapeseed oil, soybean oil, olive oil, safflower oil, cottonseed oil, sunflower oil, rice bran oil, palm oil, palm kernel oil; fish oil, tallow And animal oils such as lard, milk fat, and egg yolk oil; oils and fats that have been subjected to separation, hydrogenation, ester exchange, and the like using these as raw materials, and mixed oils thereof, and the like can be used.
  • vegetable oils such as corn oil, rapeseed oil, high cinnamon rapeseed oil, soybean oil, olive oil, safflower oil, cottonseed oil, sunflower oil, rice bran oil, palm oil, palm kernel oil
  • fish oil, tallow And animal oils such as lard, milk fat, and egg yolk oil
  • the oil-and-fat processing composition of the present invention thus obtained can be used as a liquid oil or fat such as salad oil or frying oil, a plastic oil such as margarine or shortening, or into a water-in-oil emulsion or an oil-in-water emulsion. Can be used.
  • sweets such as chewing gum, chocolate, candy, jelly, biscuits, and crackers
  • cold desserts such as ice cream and ice desserts
  • Beverages such as udon, Chinese food, spaghetti, instant food, etc .
  • Kneaded products such as kambu, bamboo rings, halves
  • seasonings such as dressings, mayonnaise, sauces
  • bread, ham Examples include soups, various retort foods, various frozen foods, and the like, and can also be used for pet food and livestock feed.
  • various vitamins such as vitamins A, D, and E may be added or used together for the purpose of fortification
  • various salts as flavoring agents, various flavors, milk-related substances, for example, whole milk powder milk , Skim milk powder, fermented milk, milk fat and the like may be added and used in combination.
  • all antioxidants and coloring agents used in ordinary water-in-oil emulsions, oil-in-water emulsions, and the like can be used.
  • the content of glycitamarin, glycillin, dehydrodariasperin C and dehydrodariasperin D in the oil / fat processing composition for preventing and / or improving lifestyle-related diseases of the present invention and the oil / fat processing composition for improving insulin resistance is as follows.
  • the life of the compound In order to exert the effect of preventing and / or improving habitual diseases, the total amount of the compound is preferably 0.01 to 10 Omg / kg body weight per adult, more preferably 0.1 to 1 Omg / kg. It is desirable that the fat-and-oil-processing composition contain an amount capable of ingesting body weight.
  • the method of the present invention for preventing and Z or improving lifestyle-related diseases include glycicoumarin and glycillin.
  • the composition comprises an oil or fat in which at least one compound selected from the group consisting of dehydrogliasperin C and dehydrodaria sperin D is dissolved.
  • the obtained MCT solution was diluted 100-fold with methanol for HPLC, and analyzed by HP LC under the following conditions.As a result, glycitamarin, glycillin, dehydrodariasperin C, and dehydrodariasperin D per gram of the MCT solution were 2.Omg each. , 1. 4mg s 6. 8mg, contained 5. 5 mg.
  • the analytical column was J, sphere ODS-H80, 4.6 x 250 mm ( ⁇ Was used at a column temperature of 40 ° C.
  • the ratio of acetonitrile to 10 mM phosphoric acid aqueous solution was kept constant at 35% from the start of analysis to 15 minutes, and then increased at a fixed ratio to 70% after 15 minutes and 65 minutes after 65 minutes.
  • the flow rate was 1 ml / min under gradient conditions that were constant at 70% up to that point.
  • the injection volume was 20 ⁇ l and the detection wavelength was 350 nm.
  • the retention times were 33.5 minutes for glycicoumarin, 38.0 minutes for dehydrogliasperin C, 49.2 minutes for glycillin, and 56.5 minutes for dehydrogliasperin D.
  • the above-mentioned MCT solution was stored at 4 ° C, 25 ° C, and 40 ° C, respectively, for 4 weeks, and the content of glycicoumarin, glycillin, dehydrogliasperin C, and dehydroglasperin D was quantified every week.
  • the storage stability was represented by the ratio of the contents at the start of storage after storage, with the contents at the start of storage being 100%.
  • Table 1 shows the results of storage at 4 ° C
  • Table 2 shows the results of storage at 25 ° C
  • Table 3 shows the results of storage at 40 ° C.
  • compound 1 represents glycicoumarin
  • compound 2 represents glycillin
  • compound 3 represents dehydrogliasperin C
  • compound 4 represents dehydrogliasperin D.
  • Example 1 The licorice hydrophobic extract used in Example 1 was dissolved in ethanol instead of Actor M-2 to obtain a 100 mg / 1 ethanol solution. This ethanol solution was diluted 100-fold with methanol for HPLC, and analyzed by HPLC.As a result, 2.4 mg and 1.6 mg of glycicumarin, glycillin, dehydrogliasperin C and dehydrodaliasperin D per lm of ethanol solution were used, respectively. It contained 7.4 mg and 5.8 mg.
  • KK-Ay mice female, 6 weeks old
  • a type 2 diabetes model animal were divided into three groups (five animals in each group), divided into groups A, B, and C, and fed the diets shown in Table 4 freely.
  • the basal diet casein 20 wt 0/0, corn starch 49.9 48% by weight
  • Shiyukurosu 10 weight 0/0 cellulose powder 5 weight 0/0
  • AIN one 93 Mineral mixture 3.5 wt 0/0
  • group A the blood glucose level of the mice increased over time, and diabetes was observed.
  • group B as in group A, the blood glucose level of the mice increased and diabetes occurred, and the effect of MCT was not observed.
  • group C the increase in the blood glucose level of the mice was significantly suppressed as compared with the groups A and B, and the diabetes preventive effect of the MCT solution of Example 1 was observed. Was observed.
  • C57BL / 6J mice female, 8-week-old were fed a high-fat, high-sugar diet with free intake for 8 weeks, resulting in dietary obesity.
  • the high-fat 'high sugar diet casein 2 5 wt 0/0, corn starch 14.869 wt%, Shiyukurosu 20 weight 0 /. , Soybean oil 2% by weight, lard 14% by weight, beef tallow 14% by weight, cellulose powder 5 wt%, AIN- 93 mineral mixture 3.5 weight 0/0, AIN- 93 vitamin mixture 1% by weight, choline bitartrate 0.
  • mice were divided into three groups (five mice in each group), which were designated as group A, group B, and group C.
  • Group A received CE-2 feed (CLEA Japan)
  • Group B received CE-2 feed supplemented with 3% by weight of MCT
  • Group C received 3% of the MCT solution of Example 1. /.
  • Actor M-2 RIKEN Vitamin Co., Ltd.
  • mice that had been deprived of the 1B diet were laparotomized under ether anesthesia, blood was collected from the abdominal aorta and sacrificed, and mesenteric fat, perirenal fat, and perineal fat were extracted and weighed. The sum of the weight of mesenteric fat, the weight of fat around the kidney, and the weight of fat around the uterus was defined as fat weight in the abdominal cavity. Table 6 shows the results. Table 6
  • Example 1 The MCT solution of Example 1 was press-fitted into the gelatin membrane using a rotary soft capsule manufacturing apparatus to obtain a soft capsule having an internal volume of 35 O mg.
  • Hardened cottonseed oil (trade name: Snow Light, Kanegafuchi Chemical Industry Co., Ltd.) 80 parts by weight, MCT solution of Example 1 20 parts by weight, unsalted butter (Four-leaf Dairy Co., Ltd.) 10 parts by weight Glycerin mono fatty acid ester (trade name: Emulgy MS, RIKEN Vitamin Strain) 0.2 parts by weight of lecithin and 0.2 parts by weight of lecithin were added and dissolved by heating at 60 ° C to prepare an oil phase.
  • An aqueous phase was prepared by dissolving 25 parts by weight of skim milk powder, 0.1 part by weight of glycerin fatty acid ester, and 0.1 part by weight of sucrose fatty acid ester in 64.6 parts by weight of water at 60 ° C. After pre-emulsifying the prepared aqueous phase and oil phase, they were sterilized at 145 ° C for 4 seconds with an ultra-high temperature instant (UHT) sterilizer. Then, after vacuum cooling, the mixture was homogenized with a homogenizer at a pressure of 10 MPa and further cooled to 10 ° C on a plate to obtain concentrated milk for processing.
  • UHT ultra-high temperature instant
  • an oil / fat composition that can be used in foods and drinks such as health foods and functional health foods (foods for specified health use, nutritional foods), pharmaceuticals, quasi-drugs, cosmetics, and the like.
  • the oil / fat processing composition of the present invention is effective for improving insulin resistance and for preventing and / or improving lifestyle-related diseases such as visceral fat obesity, type 2 diabetes, hyperlipidemia and hypertension.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Pyrane Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

L'invention concerne une composition de matière grasse traitée qui contient au moins un composé sélectionné dans le groupe constitué de la glycycmarine, la glycérine, la déhydroglyaspérine C et la déhydroglyaspérine D. Cette composition peut être utilisée dans des aliments et boissons, par exemple dans des aliments diététiques et des aliments correspondant à des demandes en matière de santé (aliments pour usages diététiques spécifiés et aliments répondant à des demandes relatives à des fonctions nutritives), des médicaments, des quasimédicaments, des cosmétiques etc. Cette composition est efficace dans le traitement de la résistance à l'insuline et dans la prévention et/ou le traitement de maladies associées au mode de vie telles que l'obésité avec dépôt interne de graisse, le diabète de type 2, l'hyperlipidémie et l'hypertension. L'invention concerne notamment une composition de matière grasse traitée dans laquelle au moins un composé sélectionné dans le groupe constitué de la glycycoumarine, de la glycérine, de la déhydroglyaspérine C et de la déhydroglyaspérine D est dissous dans de la graisse (en particulier un triglycéride d'acide gras à chaîne moyenne et/ou un glycéride partiel), ce qui augmente la stabilité du composé et améliore l'aptitude au traitement d'aliments de boissons de médicaments, de quasimédicaments de cosmétiques etc.
PCT/JP2004/000599 2003-01-24 2004-01-23 Compositions de matiere grasse traitees pour prevenir et traiter des maladies associees au mode de vie WO2004064830A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005508126A JPWO2004064830A1 (ja) 2003-01-24 2004-01-23 生活習慣病予防・改善用の油脂加工組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003016023 2003-01-24
JP2003-016023 2003-01-24

Publications (1)

Publication Number Publication Date
WO2004064830A1 true WO2004064830A1 (fr) 2004-08-05

Family

ID=32767458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/000599 WO2004064830A1 (fr) 2003-01-24 2004-01-23 Compositions de matiere grasse traitees pour prevenir et traiter des maladies associees au mode de vie

Country Status (3)

Country Link
JP (1) JPWO2004064830A1 (fr)
TW (1) TW200427410A (fr)
WO (1) WO2004064830A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114013A1 (fr) * 2006-03-31 2007-10-11 Suntory Limited Composition contenant un compose lignane
JP2008096317A (ja) * 2006-10-12 2008-04-24 Toyama Prefecture 植物が含有するフラボノイドの組成比率による品種識別法
US7943663B2 (en) 2005-09-30 2011-05-17 Suntory Holdings Limited Process and an apparatus for producing episesamin-rich compositions
CN110354119A (zh) * 2018-03-26 2019-10-22 中国农业大学 甘草香豆素在制备预防和/或治疗药物性肝损伤的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02204417A (ja) * 1989-02-02 1990-08-14 Maruzen Kasei Co Ltd 甘草疎水性フラボノイド製剤
WO2002047699A1 (fr) * 2000-12-12 2002-06-20 Kaneka Corporation Compositions de prévention ou d'amélioration de syndromes multifactoriels
WO2003037316A1 (fr) * 2001-10-11 2003-05-08 Kaneka Corporation Ligands de recepteurs actives par le proliferateur de peroxisome et procede de fabrication correspondant
JP2003252784A (ja) * 2002-02-27 2003-09-10 Kanegafuchi Chem Ind Co Ltd α−グルコシダーゼ阻害剤
JP2003274856A (ja) * 2002-03-26 2003-09-30 Kanegafuchi Chem Ind Co Ltd 甘草疎水性抽出物を含有してなる食用油脂組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02204417A (ja) * 1989-02-02 1990-08-14 Maruzen Kasei Co Ltd 甘草疎水性フラボノイド製剤
WO2002047699A1 (fr) * 2000-12-12 2002-06-20 Kaneka Corporation Compositions de prévention ou d'amélioration de syndromes multifactoriels
WO2003037316A1 (fr) * 2001-10-11 2003-05-08 Kaneka Corporation Ligands de recepteurs actives par le proliferateur de peroxisome et procede de fabrication correspondant
JP2003252784A (ja) * 2002-02-27 2003-09-10 Kanegafuchi Chem Ind Co Ltd α−グルコシダーゼ阻害剤
JP2003274856A (ja) * 2002-03-26 2003-09-30 Kanegafuchi Chem Ind Co Ltd 甘草疎水性抽出物を含有してなる食用油脂組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIBANO M. ET AL: "Studies on the index compounds for HPLC analysis of Glycyrrhiza Uralensis", HETEROCYCLES, vol. 45, no. 10, 1997, pages 2053 - 2060, XP001010595 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943663B2 (en) 2005-09-30 2011-05-17 Suntory Holdings Limited Process and an apparatus for producing episesamin-rich compositions
WO2007114013A1 (fr) * 2006-03-31 2007-10-11 Suntory Limited Composition contenant un compose lignane
US9408803B2 (en) 2006-03-31 2016-08-09 Suntory Holdings Limited Compositions containing lignan-class compounds
JP2008096317A (ja) * 2006-10-12 2008-04-24 Toyama Prefecture 植物が含有するフラボノイドの組成比率による品種識別法
CN110354119A (zh) * 2018-03-26 2019-10-22 中国农业大学 甘草香豆素在制备预防和/或治疗药物性肝损伤的药物中的应用

Also Published As

Publication number Publication date
JPWO2004064830A1 (ja) 2006-05-18
TW200427410A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
JP4685355B2 (ja) 甘草疎水性成分含有油脂組成物の製造方法
JP3512196B2 (ja) オメガ６系・オメガ３系不飽和脂肪酸のバランス調節剤を配合してなる食品組成物
US20070141220A1 (en) Composition enriched in diglyceride with conjugated linoleic acid
AU2005320579B2 (en) Sesamin/episesamin compositions
JPH09124470A (ja) 抗ストレス組成物
TW200407080A (en) Fat composition
KR20040095263A (ko) 체온상승제
TWI389697B (zh) Improve the composition of lipid metabolism
JP6010665B2 (ja) 筋肉増量剤
US20070098761A1 (en) Processed fat composition for preventing/ameliorating lifestyle-related diseases
JP2009286703A (ja) Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
JP2006306866A (ja) アディポネクチン上昇剤
JP4191420B2 (ja) 甘草疎水性抽出物を含有してなる食用油脂組成物
WO2004064830A1 (fr) Compositions de matiere grasse traitees pour prevenir et traiter des maladies associees au mode de vie
JP6131275B2 (ja) Ｉｇｆ−１産生促進剤
JP2011001348A (ja) 酒酔い又は二日酔い防止・軽減用組成物
JP2006008526A (ja) 生活習慣病予防・改善組成物
JPWO2003074042A1 (ja) 脱共役蛋白質発現亢進剤
CN111278984A (zh) 氢氧化脂肪酸的均聚物及其制造方法
JP2004018591A (ja) 油脂組成物
JP2007246471A (ja) 血中中性脂肪上昇抑制剤およびその製造方法
KR20140071675A (ko) 흑미 추출물을 포함하는 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005508126

Country of ref document: JP

122 Ep: pct application non-entry in european phase